This document serves as a formal corrigendum for the 2016 study, "Lens regeneration using endogenous stem cells with gain of visual function," originally published in Nature. While the primary focus of this update is to rectify technical errors in the original publication, it remains a vital clarification for a high-impact piece of regenerative medicine research.
Overview
This update corrects graphical and statistical reporting errors in a study demonstrating that a minimally invasive surgical technique can harness an infant's own stem cells to regrow a functional eye lens. The corrigendum ensures the accuracy of scale bars and molecular markers, while clarifying that reported variances are standard deviations, reinforcing the statistical validity of the observed visual improvements.
Addressing Congenital Cataracts
The original research addressed the challenge of treating congenital cataracts in infants. Standard treatment involves removing the clouded lens and replacing it with an artificial intraocular lens. However, this often leads to complications like inflammation and secondary "after-cataracts" because the surgery destroys the lens's natural regenerative environment.
To solve this, the authors proposed a paradigm shift: regrowing the lens instead of replacing it. They developed a surgical method to preserve Lens Epithelial Stem Cells (LESCs). This corrigendum specifically addresses errors in the original presentation of that data—including mislabeled scale bars and ambiguous statistical notation—to ensure the scientific record accurately reflects the success of this regenerative approach.
Methods and Technical Corrections
The original study introduced a "minimally invasive" surgical technique that uses a tiny incision at the periphery to remove the cataract while leaving the capsule and the resident LESCs intact. These stem cells then naturally proliferate and differentiate to form a new, transparent lens.
The corrigendum provides several key technical adjustments:
- Corrected Scale Bars: Adjustments to Figure 3e and Extended Data Figure 7b.
- Marker Placement: Rectification of molecular weight markers in protein blot assays assessing lens proteins like $\alpha$A-cry and $\beta$-actin.
- Statistical Clarification: A revised Table 1 that explicitly defines the values in parentheses as standard deviations rather than logMAR (a different scale for visual acuity), ensuring the precision of the clinical data is clear.
Key Insights: Regenerative Precision
One of the most critical biological confirmations in the study is the use of Ki67 staining to mark cellular proliferation. The correction of this data confirms that the regenerated tissue is indeed the result of active stem cell division within the preserved lens capsule.
By clarifying that the parenthetical values in the clinical data are standard deviations, the authors confirm the consistency of the visual recovery across the patient cohort. The data confirms that the new treatment leads to a steady increase in decimal acuity over six months, starting from a baseline of ~0.008 and reaching ~0.10–0.11.
Key Results: Quantitative Success
The corrected Table 1 highlights the quantitative success of the new treatment compared to the current standard. While both groups started with very low decimal acuity (approx. 0.008), the "New treatment" group achieved a decimal acuity of 0.10 (SD 0.038) in the right eye and 0.11 (SD 0.027) in the left eye by the 6-month mark.
While the "Current treatment" group showed similar decimal acuity at 6 months, the original paper emphasizes that the new technique achieves these results with significantly fewer complications and a superior physiological lens structure.
Limitations and Future Outlook
While the corrigendum focuses on data correction, it points toward the ongoing need for rigorous reporting in regenerative clinical trials. Long-term monitoring is required to ensure the regenerated lens remains clear throughout childhood. Furthermore, while this technique relies on the high regenerative capacity of infant stem cells, translating this to adult cataracts—where stem cell activity is lower—remains a significant hurdle for future research.
Summary updated